Moreover, T294-HBc VLP-induced antibodies could simultaneously bind to MTBR 1–4 [tau263–274, tau294–305, tau325–336, tau357–368, and tau294–305(P301S)], indicating that this vaccine has promising therapeutic potential for the treatment of FTD and AD. This evidence concerns the gene KRT88P and frontotemporal dementia.